



(51) International Patent Classification:

C07C 235/78 (2006.01) *A61P 25/08* (2006.01)
A61K 31/122 (2006.01) *A61P 25/16* (2006.01)
A61P 25/28 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2015/066211

(22) International Filing Date:

16 December 2015 (16.12.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/092,743 16 December 2014 (16.12.2014) US
 62/133,276 13 March 2015 (13.03.2015) US

(71) Applicant: **EDISON PHARMACEUTICALS, INC.**,
 [US/US]; 350 North Bernardo Avenue, Mountain View,
 California 94043 (US).

(72) Inventor; and

(71) Applicant : **MILLER, Guy M.** [US/US]; c/o Edison
 Pharmaceuticals, Inc., 350 North Bernardo Avenue, Moun-
 tain View, California 94043 (US).

(72) Inventors: **MOLLARD, Paul**; c/o Edison Pharmaceutic-
 als, Inc., 350 North Bernardo Avenue, Mountain View,
 California 94043 (US). **SHRADER, William D.**; c/o Edis-
 on Pharmaceuticals, Inc., 350 North Bernardo Avenue,
 Mountain View, California 94043 (US). **KHEIFETS,**
Viktoria; c/o Edison Pharmaceuticals, Inc., 350 North
 Bernardo Avenue, Mountain View, California 94043 (US).
TRIMMER, Jeffrey K.; c/o Edison Pharmaceuticals, Inc.,
 350 North Bernardo Avenue, Mountain View, California
 94043 (US).

(74) Agents: **PATHAK, Rahul** et al.; Squire Patton Boggs
 (US) LLP, 600 Hansen Way, Palo Alto, California 94304
 (US).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
 BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
 SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
 DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
 LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: POLYMORPHIC AND AMORPHOUS FORMS OF (R)-2-HYDROXY-2-METHYL-4-(2,4,5-TRIMETHYL-3,6-DIOX-
 OCYCLOHEXA-1,4-DIENYL)BUTANAMIDE



(57) Abstract: Disclosed herein are polymorphic and amorphous forms of anhydrate, hydrate, and solvates of (R)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide and methods of using such compositions for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases of aging. Further disclosed are methods of making such polymorphic and amorphous forms.